Bioatla Stock Analysis

BCAB Stock  USD 1.75  0.05  2.78%   
Bioatla is undervalued with Real Value of 4.79 and Target Price of 14.0. The main objective of Bioatla stock analysis is to determine its intrinsic value, which is an estimate of what Bioatla is worth, separate from its market price. There are two main types of Bioatla's stock analysis: fundamental analysis and technical analysis.
The Bioatla stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Bioatla's ongoing operational relationships across important fundamental and technical indicators.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioatla. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Bioatla Stock refer to our How to Trade Bioatla Stock guide.

Bioatla Stock Analysis Notes

About 61.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.31. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bioatla recorded a loss per share of 2.48. The entity had not issued any dividends in recent years. BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California. Bioatla operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. For more info on Bioatla please contact Jay Short at 858 558 0708 or go to

Bioatla Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Bioatla's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Bioatla or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Bioatla generated a negative expected return over the last 90 days
Bioatla has high historical volatility and very poor performance
Bioatla may become a speculative penny stock
Net Loss for the year was (123.46 M) with loss before overhead, payroll, taxes, and interest of (79.35 M).
Bioatla currently holds about 178.12 M in cash with (104.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 61.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Disposition of 555 shares by Sievers Eric of Bioatla at 3.37 subject to Rule 16b-3

Bioatla Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bioatla previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
28th of March 2024
Upcoming Quarterly Report
9th of May 2024
Next Financial Report
31st of December 2023
Next Fiscal Quarter End
28th of March 2024
Next Fiscal Year End
30th of September 2023
Last Quarter Report
31st of December 2022
Last Financial Announcement

Bioatla Largest EPS Surprises

Earnings surprises can significantly impact Bioatla's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Bioatla Stock Institutional Investors

Boxer Capital Llc2024-03-31
686.3 K
Massachusetts Financial Services Company2024-03-31
526.5 K
Healthcare Of Ontario Pension Plan Trust Fund2024-03-31
512.3 K
Norges Bank2023-12-31
488.2 K
Northern Trust Corp2024-03-31
353.9 K
Mccormack Advisors International2024-03-31
330.4 K
Two Sigma Advisers, Llc2024-03-31
299.7 K
Bank Of Montreal2024-03-31
260.7 K
Bmo Capital Markets Corp.2024-03-31
260.7 K
Soleus Capital Management, L.p.2024-03-31
4.1 M
Blackrock Inc2024-03-31
2.8 M
Note, although Bioatla's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Bioatla Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 83 M.

Bioatla Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(1.03)(1.08)
Return On Capital Employed(1.42)(1.35)
Return On Assets(1.03)(1.08)
Return On Equity(1.75)(1.66)

Management Efficiency

Bioatla has return on total asset (ROA) of (0.5328) % which means that it has lost $0.5328 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1568) %, meaning that it created substantial loss on money invested by shareholders. Bioatla's management efficiency ratios could be used to measure how well Bioatla manages its routine affairs as well as how well it operates its assets and liabilities. As of July 16, 2024, Return On Tangible Assets is expected to decline to -1.08. The current year's Return On Capital Employed is expected to grow to -1.35. At present, Bioatla's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 217.8 M, whereas Other Assets are forecasted to decline to 0.95.
Last ReportedProjected for Next Year
Book Value Per Share 1.48  2.06 
Tangible Book Value Per Share 1.48  2.06 
Enterprise Value Over EBITDA(0.07)(0.07)
Price Book Value Ratio 1.66  1.75 
Enterprise Value Multiple(0.07)(0.07)
Price Fair Value 1.66  1.75 
Enterprise Value9.8 M9.3 M
The analysis of Bioatla's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Bioatla's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Bioatla Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Return On Assets
Return On Equity

Technical Drivers

As of the 16th of July 2024, Bioatla shows the Standard Deviation of 9.59, mean deviation of 6.41, and Risk Adjusted Performance of (0.03). Bioatla technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Bioatla Price Movement Analysis

Execute Study
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Bioatla middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Bioatla. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Bioatla Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bioatla insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bioatla's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bioatla insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Bioatla Outstanding Bonds

Bioatla issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bioatla uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bioatla bonds can be classified according to their maturity, which is the date when Bioatla has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Bioatla Predictive Daily Indicators

Bioatla intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bioatla stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Bioatla Forecast Models

Bioatla's time-series forecasting models are one of many Bioatla's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bioatla's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Bioatla Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bioatla prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bioatla shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Bioatla. By using and applying Bioatla Stock analysis, traders can create a robust methodology for identifying Bioatla entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(438.85)(416.91)
Operating Profit Margin(443.62)(421.44)
Net Loss(438.87)(416.92)
Gross Profit Margin(4.97)(4.72)

Current Bioatla Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bioatla analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bioatla analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
14.0Strong Buy4Odds
Bioatla current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Bioatla analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bioatla stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bioatla, talking to its executives and customers, or listening to Bioatla conference calls.
Bioatla Analyst Advice Details

Bioatla Stock Analysis Indicators

Bioatla stock analysis indicators help investors evaluate how Bioatla stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bioatla shares will generate the highest return on investment. By understating and applying Bioatla stock analysis, traders can identify Bioatla position entry and exit signals to maximize returns.
Begin Period Cash Flow215.5 M
Common Stock Shares Outstanding47.8 M
Total Stockholder Equity70.7 M
Property Plant And Equipment Net3.1 M
Cash And Short Term Investments111.5 M
Cash111.5 M
Accounts Payable3.8 M
Net Debt-109 M
50 Day M A1.9629
Total Current Liabilities28.3 M
Other Operating Expenses129.7 M
Non Current Assets Total3.3 M
Non Currrent Assets Other154 K
Stock Based Compensation13.5 M

Complementary Tools for Bioatla Stock analysis

When running Bioatla's price analysis, check to measure Bioatla's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioatla is operating at the current time. Most of Bioatla's value examination focuses on studying past and present price action to predict the probability of Bioatla's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioatla's price. Additionally, you may evaluate how the addition of Bioatla to your portfolios can decrease your overall portfolio volatility.
List of equity sectors categorizing publicly traded companies based on their primary business activities
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation